Inactive Instrument

CrystalGenomics Inc. Stock price Korea S.E.

Equities

Pharmaceuticals

Sales 2022 38.64B 28.67M 0 Sales 2023 4.88B 3.62M 0 Capitalization 208B 155M 0
Net income 2022 -23.87B -17.71M - Net income 2023 -48.92B -36.3M - EV / Sales 2022 5.93 x
Net cash position 2022 11.83B 8.78M 0 Net cash position 2023 12.29B 9.12M 0 EV / Sales 2023 40.2 x
P/E ratio 2022
-10.1 x
P/E ratio 2023
-4.2 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 75.48%
More Fundamentals * Assessed data
PanGen Biotech Inc. announced that it has received KRW 3.999986631 billion in funding from CrystalGenomics Invites Co., LTD., Huons Co., Ltd., Hwail Pharmaceutical Co.,Ltd. CI
PanGen Biotech Inc. announced that it expects to receive KRW 3.999986631 billion in funding from CrystalGenomics Invites Co., LTD., Huons Co., Ltd., Hwail Pharmaceutical Co.,Ltd. CI
CrystalGenomics Invites Co., LTD. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Hwail Pharmaceutical Co.,Ltd. announced extension to the offering period CI
An unknown buyer cancelled the acquisition of 2.40% stake in CrystalGenomics, Inc. from Kumho HT, Inc. CI
CrystalGenomics Invites Co., LTD. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Hwail Pharmaceutical Co.,Ltd. announced that it expects to receive KRW 25.999996662 billion in funding from Osung Advanced Materials Co., Ltd., Kumho HT, Inc, CrystalGenomics Invites Co., LTD. CI
Crystal Bio Sciences Co., Ltd announced that it has received KRW 10 billion in funding from CrystalGenomics Invites Co., LTD. CI
CrystalGenomics Invites Co., LTD.(KOSDAQ:A083790) dropped from S&P Global BMI Index CI
CrystalGenomics Invites Co., LTD. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
CrystalGenomics, Inc. announced that it has received KRW 62.427998592 billion in funding from New Lake Invites Investment Co., Ltd., Osung Advanced Materials Co., Ltd. CI
CrystalGenomics Invites Co., LTD. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
An unknown buyer agreed to acquire approximately 2.40% stake in CrystalGenomics, Inc. from Kumho HT, Inc for KRW 28 billion. CI
CrystalGenomics, Inc. agreed to acquire 20.43% stake in PanGen Biotech Inc. from the group of shareholders for approximately KRW24 billion. CI
CrystalGenomics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
More news
Managers TitleAgeSince
Chief Executive Officer 75 99-12-31
Comptroller/Controller/Auditor 52 -
Members of the board TitleAgeSince
Chief Executive Officer 75 99-12-31
Director/Board Member 59 17-03-30
Director/Board Member 64 -
More insiders
CrystalGenomics Invites Co Ltd is a Korea-based company principally engaged in the development and manufacturing of pharmaceuticals. The Company operates through three segments. The fFinished Pharmaceuticals Manufacturing segment is engaged in the manufacture and sale of finished pharmaceuticals. The Pharmaceutical R&D Division is engaged in the provision of clinical trial analysis and technical services and the sale of new drugs. The segment also operates in the real estate leasing business. The Others segment engages in the manufacture and sale of hot fats and other household items.
More about the company
  1. Stock
  2. Equities
  3. Stock CrystalGenomics Invites Co., LTD.
  4. Stock CrystalGenomics Inc. - Korea S.E.